Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Quality of Life
Interventions
DRUG

Exenatide

"Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.~The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .~The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier."

DRUG

Insulin

"Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.~The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.~The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al."

Trial Locations (1)

25030

Post operative intensive care unit of the cardiac surgery department, Besançon

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

lead

Centre Hospitalier Universitaire de Besancon

OTHER

NCT02432976 - Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients | Biotech Hunter | Biotech Hunter